Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 1:11:664741.
doi: 10.3389/fonc.2021.664741. eCollection 2021.

Angiotensin System Inhibitors May Improve Outcomes of Patients With Castration-Resistant Prostate Cancer During Abiraterone Acetate Treatment-A Cardio-Oncology Study

Michał Wilk  1 , Anna Waśko-Grabowska  1 , Iwona Skoneczna  1   2 , Sebastian Szmit  3
Affiliations

Angiotensin System Inhibitors May Improve Outcomes of Patients With Castration-Resistant Prostate Cancer During Abiraterone Acetate Treatment-A Cardio-Oncology Study

Michał Wilk et al. Front Oncol. .

Abstract

Background: Abiraterone acetate (ABI) therapy improves overall survival in metastatic prostate cancer (PC) patients; however, this effect may be diminished by concurrent comorbidities. We aimed to evaluate the influence of pre-existing chronic diseases and concomitant medications on the course of ABI treatment among post-chemotherapy patients with metastatic castration-resistant prostate cancer patients (mCRPC).

Methods: From the Polish National Health Fund database, we identified 93 post-chemotherapy, mCRPC patients, who were qualified for ABI treatment in our oncology center between 2014 and 2018. Survival curves and Cox proportional hazard models (univariate and multivariate) were used to determine the predictors for longer time to treatment failure (TTF) of ABI therapy.

Results: Median TTF was 9,8 months (IQR: 0,6-56,5) Factors associated with longer TTF were: well controlled hypertension (HR, 0.59; 95% CI. 0.38-0.90; p = 0.02), stable coronary artery disease (HR, 0.56; 95% CI, 0.33-0.95; p=0.03), the use of angiotensin system inhibitor (ASi) (HR, 0.61; 95% CI 0.4-0.94; p = 0,02). Patients who were receiving ASi had median TTF of 12.2 months versus 5.8 months in men who did not receive ASi before ABI initiation. At the start of ABI therapy, the aforementioned groups did not differ in terms of well-known prognostic factors: Gleason score, PSA level, or the number of patients with visceral metastases. In a multivariate analysis, the use of ASi remained statistically significant, even after adjustment for well-known oncological factors (HR, 0.57; 95% CI, 0.34-0.98; p = 0.04).

Conclusions: The use of ASi may enhance and prolong ABI therapy in post-docetaxel mCRPC patients and may potentially be considered a new, non-oncological, predictive factor for longer TTF. This association requires a prospective validation.

Keywords: abiraterone; angiotensin system inhibitor; cardio-oncology; cardiovascular; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

IS reports receiving research grants (not related to this study) and lecture fees from Janssen. SS reports receiving lecture fee from Janssen, unrelated to the subject of this study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Kaplan-Meier curves of time to treatment failure depending on the ASi therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin (2020) 70:7–30. 10.3322/caac.21590 - DOI - PubMed
    1. Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, et al. . European cancer mortality predictions for the year 2019 with focus on breast cancer. Ann Oncol (2019) 30:781–7. 10.1093/annonc/mdz051 - DOI - PubMed
    1. O’Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, et al. . Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer (2004) 90:2317–25. 10.1038/sj.bjc.6601879 - DOI - PMC - PubMed
    1. Wilk M, Waśko-Grabowska A, Szmit S. Cardiovascular Complications of Prostate Cancer Treatment. Front Pharmacol (2020) 11:1828. 10.3389/fphar.2020.555475 - DOI - PMC - PubMed
    1. Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, et al. . Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol (2010) 28:3448–56. 10.1200/JCO.2010.29.1567 - DOI - PubMed